Radebeul, Germany, May 09, 2014 - BioCrea GmbH (BioCrea), the first-in-class CNS drug discovery specialist, today announced that Chief Executive Officer, Dr. Tom Kronbach, will present at BioTrinity 2014, Europe’s leading Biopartnering and Investment Conference, to be held on 12-14 May in London.
Tom Kronbach will be presenting on May 13, 2014 at 13:50 BST in the Alsace Room, Mezzanine Floor, Novotel London West, UK.
“This is a wonderful opportunity for BioCrea to present its lead programs and novel discovery platforms to over 30 major pharmaceutical companies,” said Dr. Tom Kronbach, CEO of BioCrea. “In partnering terms, we will talk about our two unique proprietary small molecule programs: Long-term acting GABAA positive allosteric modulators (LT GABAA PAMs) to treat epilepsy plus autism; and NMDA receptor 2B (NR2B) negative allosteric modulators (NAMs) to treat depression. Both programs are expected to reach the IND-enabling study phase later this year.”
Founded and produced by OBN, BioTrinity has become the “must attend” life sciences conference for emerging European companies, investors and partners. The conference is now in its eighth year. BioTrinity has grown rapidly over recent years, and is now located in London to accommodate increased interest. More than 1000 senior executives and decision makers from emerging and established companies across the life sciences sector and investment firms are expected to meet one-on-one, attend panel discussions and workshops, or browse the company showcases, seeking out their next deals.
About BioCrea
BioCrea, the Radebeul-based first-in-class drug discovery specialist validated through pharma partnerships, has established a number of programs in neurological and psychotic disorders. Its proven expertise is based on proprietary compound libraries, medicinal chemistry, molecular modeling and advanced screening technologies. BioCrea uses this expertise in an innovative multi-parameter optimization approach to generate and deliver CNS drug candidates that offer significant potential for greater efficacy and tolerability. Moreover, the patient-derived stem cell (iPSC) platform has been successfully developed to discover high value preclinical drug candidates for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS, Lou Gehrig’s disease). BioCrea was awarded Top Innovator status of the “Top 100" Most Innovative Companies in Germany 2012 by compamedia GmbH. For more information, please visit www.biocrea.com.
About OBN
OBN is the membership organisation supporting and bringing together the UK’s emerging life sciences companies, corporate partners and investors. Our Membership of around 300 companies, spread across the Golden Triangle (formed by the cities of Oxford, Cambridge and London) and beyond to Nottingham, Manchester and Scotland, benefits from tailored networking and partnering events, group purchasing, advice and advocacy.
OBN founded and produces BioTrinity, Europe’s largest annual Biopartnering and Investment Conference for emerging companies. Attracting around 1,000 senior delegates from Europe, Asia and North America, BioTrinity generates more R&D-company-to-investor interactions than any similar European event. For further information on OBN and its activities, visit: www.obn.org.uk.
Contact
Dr. Tom Kronbach
CEO, BioCrea GmbH
Tel.: +49 351 / 4043 3332
Fax: +49 351 / 4043 3216
tom.kronbach@biocrea.com
Help employers find you! Check out all the jobs and post your resume.
